<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Helwick, Caroline</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Freeman, Roy</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Diabetic Peripheral Neuropathy: More Effective Treatments Needed</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">26-27</style></pages><abstract><style  face="normal" font="default" size="100%">In a pooled analysis of 1,510 patients enrolled in seven randomized controlled trials, pregabalin (150–600 mg/day) provided significant improvements in pain, sleep interference due to pain, and global health. Improvements in pain were dose-related; a clinically meaningful (=30%) improvement in pain was noted by 43%–62%, though 37% of placebo patients also reported this level of improvement.</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">7</style></volume></record></records></xml>